Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980705 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of SUNPG1622
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT02980705: Clinical Trial Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT02980705 is a Phase 2 study that was terminated before completion, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02980705, a Phase 2 study, was terminated before completion, sponsored by Sun Pharmaceutical Industries Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
Primary Outcome
Percentage of subjects who achieve improvement of ≥ 40% and absolute improvement of ≥ 20 units from baseline in a visual analog scale (0 \[no disease activity\]-100 \[high disease activity\]). The results for this endpoint is as per the Cochran-Mantel-Haenszel Analysis of ASAS20 Response Rates (Full Analysis Set).
Interventions
- DRUG Placebo dose
- DRUG SUNPG1622 I dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-09-03 |
| Phase | Phase 2 |
Why NCT02980705 stopped before completion
NCT02980705 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo dose is the first listed.
NCT02980705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02980705 about?
NCT02980705 is a clinical study titled "Efficacy and Safety Study of SUNPG1622". This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
What is the current status of trial NCT02980705?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2017-11-06. Estimated completion is 2019-09-03.
What interventions are being tested in trial NCT02980705?
The interventions under investigation include: Placebo dose (DRUG), SUNPG1622 I dose (DRUG).
Who is sponsoring clinical trial NCT02980705?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02980705's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI